David A Mankoff, MD, PhD
David A Mankoff, MD, PhD
Professor of Radiology
Department: Radiology
Contact information
Penn Medicine
Perelman School of Medicine
University of Pennyslvania Health System
3400 Spruce Street
Philadephia, PA 19104
Perelman School of Medicine
University of Pennyslvania Health System
3400 Spruce Street
Philadephia, PA 19104
Office: 215-615-3687
Fax: 215-349-5843
Fax: 215-349-5843
Email:
david.mankoff@uphs.upenn.edu
david.mankoff@uphs.upenn.edu
Education:
B.S. (Physics)
Yale University, 1981.
M.D. (Medicine)
University of Pennsylvania, 1988.
Ph.D (Bioengineering)
University of Pennsylvania, 1988.
Permanent linkB.S. (Physics)
Yale University, 1981.
M.D. (Medicine)
University of Pennsylvania, 1988.
Ph.D (Bioengineering)
University of Pennsylvania, 1988.
Selected Publications
Specht JM, Mankoff DA: Advances in molecular imaging for breast cancer detection and characterization. Br Cancer Res 14: 206 (16 March 2012) 2012. Br Cancer Res 14: 206 , March 2012.Abella A, Alessio AM, Mankoff DA, MacDonald LR, Vaquero JJ, Desco M, Kinahan PE: Accuracy of CT-Based attenuation correction in PET/CT bone imaging. Phys Med Biol, in press, 2012. Phys Med Biol, in press 2012.
Mankoff DA, Link JM, Linden, HM: Steroid hormone ligands for the estrogen receptor. Targeted Molecular Imaging. Eckelman W and Welch M, eds. Taylor & Francis Group, LLC, Boca Raton, FL, 16:279-303, 2012.
Mankoff DA, Specht JM, Eubank WB, Kessler L.: 18F]Fluorodeoxyglucose positron emission tomography-computed tomography in breast cancer: when... and when Not? J Clin Oncol, epub 2012.
Doot RK, Kurlan BF, Kinahan PK, Mankoff DA: Design considerations for using PET as a response measure in single- and multi-center clinical trials. Acad Radiol 19: 814-190, 2012.
Tromberg BJ, Butler JA, Mankoff DA, Isakoff SJ, Hylton HM, Yodh AG, Boas D, Paulsen K, Pogue BW, Kaufman PA, Mehta RS, Carpenter RM, Cerussi A, Zhang Z, Hartfeil DM, L'Heureux D: ACRIN 6691 monitoring and predicting breast cancer neoadjuvant chemotherapy response using diffuse optical spectroscopic imaging (DOSI). J Clin Oncol 29 (suppl; abstr TPS249), 2011.
Kurland BF, Peterson LM, Lee JH, Linden HM, Schubert EK, Dunnwald LK, Link JM, Krohn KA, Mankoff DA: Between-patient and within-patient (site-to-site) variability in estrogen receptor binding, measured in vivo by 18F-fluoroestradiol (FES) PET. J Nucl Med 38: 969-978, 2011.
Surti S, Scheuermann J, El Fakhri G, Daube-Witherspoon ME, Lim R, Abi-Hatem N, Moussallem E, Benard F, Mankoff D, Karp JS: Impact of time-of-flight PET on whole-body oncologic studies: a human observer lesion detection and localization study. J Nucl Med 52: 712 – 719, 2011.
Dunnwald LK, Doot RK, Specht JM, Gralow JR, Ellis GK, Livingston RB, Linden HM, Gadi V, Kurland BF, Schubert EK, Muzi M, Mankoff DA: PET tumor metabolism in locally advanced breast cancer patients undergoing neoadjuvant chemotherapy: value of static versus kinetic measures of fluorodeoxyglucose uptake. Clin Cancer Res 17:2400-2409, 2011.
Mankoff DA, Linden HM, Link J, Kurland BF, Schubert EK, Peterson L, Gadi VK, Specht JM, Shankar L, Eary JF: NCI-sponsored phase II study of [18f]fluoroestradiol (FES) as a marker of hormone sensitivity of metastatic breast cancer: Initial results. J Clin Oncol 29 (suppl; abstr e11104), 2011.